<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106020">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02074462</url>
  </required_header>
  <id_info>
    <org_study_id>VCZ-13O30</org_study_id>
    <nct_id>NCT02074462</nct_id>
  </id_info>
  <brief_title>Effect of Inflammation on Voriconazole Concentration</brief_title>
  <official_title>Managing Voriconazole Exposure During Severe Infection; Effect of Inflammation on Voriconazole Metabolic Ratio</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Voriconazole is a broad-spectrum antifungal agent. There is evidence for a relation between
      the efficacy and safety of voriconazole and voriconazole trough concentrations. There are
      several factors that could influence voriconazole concentrations. Inflammation could be one
      of these factors. In a retrospective study was observed  that reduced metabolism of
      voriconazole was related to inflammation in patients with severe infections. Reduced
      metabolism of voriconazole resulted in high voriconazole levels and low N-oxide metabolite
      (inactive metabolite of voriconazole) levels. The purpose of this study is to determine an
      algorithm to guide dosing of voriconazole during severe inflammation and to develop a
      multiple linear regression model to describe the contribution of CRP concentrations to the
      variability in voriconazole levels and metabolic ratio.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Plamsa concentration of voriconazole and voriconazole N-oxide in patients during a severe inflammation</measure>
    <time_frame>Up to 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of voriconazole and voriconazole N-oxide will be determined using a validated method involving LC-MS/MS</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Inflammation</condition>
  <condition>Fungal Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the University Medical Center Groningen who receive voriconazole
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age â‰¥ 18 yrs

          -  treatment with voriconazole

          -  written informed consent

        Exclusion Criteria:

          -  concomitantly using a strong inhibitor or inducer of CYP P450
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan-Willem C Alffenaar, PharmD, PhD</last_name>
    <phone>+31503614071</phone>
    <email>j.w.c.alffenaar@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan-Willem C Alffenaar, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Voriconazole</keyword>
  <keyword>CRP</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
